Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
TJ202 + dexamethasone
- Development stage
- Phase 2
- Lead developer
- I-MAB
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous, Oral
01
Overview
TJ202 (also known as MOR202) is an investigational human monoclonal antibody targeting CD38, a surface antigen highly expressed on multiple myeloma cells. It is derived from MorphoSys’s HuCAL antibody technology and works by recruiting immune effector cells to kill tumor cells through mechanisms such as antibody-dependent cellular cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP), but not complement dependent cytotoxicity. Dexamethasone is a synthetic corticosteroid that mimics the effects of cortisol, reducing inflammation and suppressing immune responses. The combination of TJ202/MOR202 with dexamethasone has been studied primarily for the treatment of relapsed/refractory multiple myeloma, showing promising efficacy and tolerability in clinical trials[5][6][8]. I-Mab holds exclusive development and commercialization rights for TJ202/MOR202 in Greater China, while MorphoSys continues global development efforts.
02
Targets
CD38 (Cluster of Differentiation 38)GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on TJ202 + dexamethasone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on TJ202 + dexamethasone.